Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study Of Lisaftoclax (APG-2575) In Combination With Azacitidine (AZA) In Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.
-
A Phase 1, Open-Label, Dose-Escalation With Expansion Study Of SX-682 Alone And In Combination With Oral Or Intravenous Decitabine In Subjects With Myelodysplastic Syndrome
Jacksonville, FL
This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).
-
Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial Of Quizartinib Administered In Combination With Induction And Consolidation Chemotherapy And Administered As Maintenance Therapy In Adult Patients With Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia
Scottsdale/Phoenix, AZ
Jacksonville, FL
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
.